- World rank, all time
- #17,843 of 42,892
- Rank in United States
- #3,880 of 8,685
- Research works
- 146 ▼ 5% vs 2013–17
- Citations
- 2.6k 18.0 per fractional work
- Top-10% rate
- 15.1% record average 16.5%
- Open access
- 43% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 20.5×. Every wedge is a field page.
- Immunology and Microbiology 20.5×
- Biochemistry, Genetics and Molecular Biology 3.9×
- Medicine 2.6×
- Economics, Econometrics and Finance 1.1×
- Veterinary 1.1×
- Neuroscience 0.6×
- Materials Science 0.6×
- Chemistry 0.5×
- Pharmacology, Toxicology and Pharmaceutics 0.4×
- Dentistry 0.2×
- Engineering 0.2×
- Physics and Astronomy 0.1×
Who are the top researchers at Celldex Therapeutics (United States)?
Ranked on the composite score, Michael Yellin, Tibor Keler and Henry C. Marsh lead among researchers whose main affiliation is Celldex Therapeutics (United States).
- 1 Michael Yellin United States · #156,946 worldwide 247 citations · 37 works
- 2 Tibor Keler United States · #157,163 worldwide 258 citations · 57 works
- 3 Henry C. Marsh United States · #207,917 worldwide 166 citations · 21 works
- 4 Laura Vitale United States · #907,217 worldwide 51 citations · 21 works
Which keywords describe research at Celldex Therapeutics (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, Inflammation, Immunity, Tumor Microenvironment, Tumor Regression, Cancer and Monoclonal Antibodies.
- Asthma
- Autoantibodies
- Development
- Viral Vectors
- AAV
- Mast Cells
- Allergic Disease
- Nanoparticles
- Cancer Therapy
- Chimeric Antigen Receptor
- Tumor Targeting
- PD-1 and PD-L1
- Gene Therapy
- Fc Receptors
- Tumor Antigen
- Antigen Presentation
- Tumor Regression
- Tumor Microenvironment
- Cancer
- Immunotherapy
- Cancer Immunotherapy
- Inflammation
- Immunity
- Monoclonal Antibodies
- Dendritic Cells
- Innate Immunity
- Vaccine Adjuvants
- Therapeutic Antibodies
- Immune Checkpoint Blockade
- Lymphoma
- CAR T Cells
- Epidemiology
- Immune Response
- Cytokines
- Chemotherapy
- T Cell Activation
- Angiogenesis
- Cell Proliferation
- Targeted Therapy
- PET Imaging
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer Immunotherapy6▲ 93×3 topics
- Immunotherapy6▲ 20×10 topics
- Inflammation5▲ 5.8×20 topics
- Cancer4▲ 6.6×14 topics
- Immunity4▲ 21×3 topics
- Tumor Microenvironment4▲ 19×5 topics
- Monoclonal Antibodies4▲ 91×2 topics
- Tumor Regression4▲ 76×2 topics
- Dendritic Cells3▲ 85×3 topics
- Antigen Presentation3▲ 86×2 topics
- Innate Immunity3▲ 24×3 topics
- Tumor Antigen3▲ 119×1 topic
- Vaccine Adjuvants3▲ 119×1 topic
- Fc Receptors3▲ 131×1 topic
- Therapeutic Antibodies3▲ 103×1 topic
- Gene Therapy3▲ 35×3 topics
- Immune Checkpoint Blockade3▲ 60×1 topic
- PD-1 and PD-L13▲ 60×1 topic
- Lymphoma3▲ 40×3 topics
- Tumor Targeting3▲ 35×3 topics
- CAR T Cells3▲ 82×1 topic
- Chimeric Antigen Receptor3▲ 82×1 topic
- Epidemiology3▲ 1.50×14 topics
- Cancer Therapy2▲ 9.6×7 topics
- Immune Response2▲ 8.1×7 topics
- Nanoparticles2▲ 3.6×3 topics
- Cytokines2▲ 15×3 topics
- Allergic Disease2▲ 250×1 topic
- Chemotherapy2▲ 5.3×7 topics
- Mast Cells2▲ 250×1 topic
- T Cell Activation2▲ 96×2 topics
- AAV2▲ 88×1 topic
- Angiogenesis2▲ 10×7 topics
- Viral Vectors2▲ 88×1 topic
- Cell Proliferation1▲ 37×2 topics
- Development1▲ 9.0×2 topics
- Targeted Therapy1▲ 14×4 topics
- Autoantibodies1▲ 12×5 topics
- PET Imaging1▲ 16×3 topics
- Asthma1▲ 25×2 topics
Which research topics does Celldex Therapeutics (United States) publish most on?
By volume in 2022–2025: Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Cancer Immunotherapy and Biomarkers and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Immunotherapy and Immune Responses Immunology 3 works
- 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 3 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 4 CAR-T cell therapy research Oncology 3 works
- 5 Mast cells and histamine Immunology 2 works
- 6 Virus-based gene therapy research Genetics 2 works
- 7 Melanoma and MAPK Pathways Molecular Biology 1 works
- 8 Nanoplatforms for cancer theranostics Biomedical Engineering 1 works
- 9 Indian Economic and Social Development Economics and Econometrics 1 works
- 10 Cancer Research and Treatments Biotechnology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Celldex Therapeutics (United States)'s research output changed?
Output in 2018–2022 was 5% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.